We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor... Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025. Show more
Ask ADVFN Intelligence (AI)
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.82 | 24.0614334471 | 11.72 | 16.22 | 11.4109 | 575565 | 14.6693724 | CS |
| 4 | 1.15 | 8.58849887976 | 13.39 | 16.22 | 8.91 | 521140 | 12.16512278 | CS |
| 12 | 1.66 | 12.8881987578 | 12.88 | 16.68 | 8.91 | 490020 | 12.90037465 | CS |
| 26 | -8.16 | -35.9471365639 | 22.7 | 28.09 | 8.91 | 453966 | 15.28208347 | CS |
| 52 | -11.71 | -44.6095238095 | 26.25 | 28.09 | 8.91 | 452070 | 16.77182389 | CS |
| 156 | -11.71 | -44.6095238095 | 26.25 | 28.09 | 8.91 | 452070 | 16.77182389 | CS |
| 260 | -11.71 | -44.6095238095 | 26.25 | 28.09 | 8.91 | 452070 | 16.77182389 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
